Update on the management of Philadelphia chromosome positive chronic myelogenous leukemia: role of nilotinib

Update on the management of Philadelphia chromosome positive chronic myelogenous leukemia: role of nilotinib

Josephine Emole,1 Taiwo Talabi,2 Javier Pinilla-Ibarz1 1Department of Malignant Hematology, 2Moffitt Program for Outreach Wellness Education and Resources, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA Abstract: Chronic myelogenous leukemia (CML) is a pluripotent stem cell dise...

Full description

Bibliographic Details
Main Authors:	Emole J, Talabi T, Pinilla-Ibarz J
Format:	Article
Language:	English
Published:	Dove Medical Press 2016-02-01
Series:	Biologics : Targets & Therapy
Subjects:	chronic myelogenous leukemia nilotinib tyrosine kinase inhibitor
Online Access:	https://www.dovepress.com/update-on-the-management-of-philadelphia-chromosome-positive-chronic-m-peer-reviewed-article-BTT

Similar Items

A rare case of hypocalcemia induced by nilotinib
by: Marija Petrić, et al.
Published: (2017-03-01)

Molecular response in long-term monitoring of patients with chronic myelogenic leukemia (CML) on nilotinib therapy
by: Dragomira Nikolova, et al.
Published: (2021-01-01)

Thyroid dysfunction in chronic myeloid leukemia patients on nilotinib
by: Khaleed J Khaleel, et al.
Published: (2018-01-01)

Imatinib resistance was reversed by nilotinib in the acute transformation of chronic myeloid leukemia: A case report
by: Meng Xiao, et al.
Published: (2017-12-01)

Aortic Stenosis and the Tyrosine Kinase Inhibitor Nilotinib in Chronic Myeloid Leukemia
by: Miguel Carracedo, PhD, et al.
Published: (2020-03-01)

Debating Frontline Therapy in Chronic Myeloid Leukemia
by: Xia Bi, et al.
Published: (2021-09-01)

The treatment of pediatric chronic myelogenous leukemia in the imatinib era
by: Jae Wook Lee, et al.
Published: (2011-03-01)

Early and sustained deep molecular response achieved with nilotinib in high Sokal risk chronic myeloid leukemia patients
by: Zaidi U, et al.
Published: (2019-02-01)

Successful Nilotinib Treatment in a Child with Chronic Myeloid Leukemia
by: Hassan A. Al-Jafar, et al.
Published: (2015-03-01)

Pharmacoeconomic modeling of target therapy of chronic myeloid leukemia in remission
by: V. A. Shuvaev, et al.
Published: (2015-01-01)

Pharmacoeconomic modeling of target therapy of chronic myeloid leukemia in remission
by: V. A. Shuvaev, et al.
Published: (2015-01-01)

Successful nilotinib therapy in a CML affected patient with A380T, P407S and V468A mutations, and a previous suboptimal cytogenetic response to imatinib
by: Fabio Stagno, et al.
Published: (2015-10-01)

Ruxolitinib/nilotinib cotreatment inhibits leukemia-propagating cells in Philadelphia chromosome-positive ALL
by: Yuan Kong, et al.
Published: (2017-08-01)

Clinical Importance of Drug Adherence during Tyrosine Kinase Inhibitor Therapy for Chronic Myelogenous Leukemia in Chronic Phase
by: Yasuhiro Maeda, et al.
Published: (2019-10-01)

Aurora kinase inhibitors: which role in the treatment of chronic myelogenous leukemia patients resistant to imatinib?
by: Giovanni Martinelli, et al.
Published: (2009-02-01)

Accelerated Phase Chronic Myeloid Leukemia and Treatment Free Remission Maintained After Five Years of Nilotinib: A Case Report
by: Isabella Capodanno, et al.
Published: (2021-06-01)

Management of a 75-Year-Old Lady with Refractory Chronic Myelogenous Leukemia
by: Philip T. Sobash, et al.
Published: (2020-05-01)

Nilotinib for the frontline treatment of chronic myeloid leukemia carrying the p230 transcript: dream or reality?
by: Maurizio eCapuozzo, et al.
Published: (2014-02-01)

Cardiovascular and metabolic problems associated with application of second generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia
by: O. Y. Vinogradova
Published: (2015-10-01)

Aldo-keto reductase inhibitors increase the anticancer effects of tyrosine kinase inhibitors in chronic myelogenous leukemia
by: Megumi Kikuya, et al.
Published: (2021-09-01)

Myriads of cutaneous manifestations with Nilotinib, treated by acitretin – a case report
by: Amrita A Hongal, et al.
Published: (2020-01-01)

Nilotinib impairs skeletal myogenesis by increasing myoblast proliferation
by: Osvaldo Contreras, et al.
Published: (2018-02-01)

Pharmacoeconomic analysis of treatment with nilotinib as the second line therapy in patients with chronic myeloid leukemia
by: N. A. Avxentyev, et al.
Published: (2018-08-01)

OCT-Based Management of Nilotinib-Associated CAD in a Patient With Chronic Myeloid Leukemia
by: Hiroyuki Kiriyama, MD, et al.
Published: (2019-12-01)

Philadelphia chromosome-positive acute lymphoblastic leukemia in childhood
by: Hong Hoe Koo
Published: (2011-03-01)

Dose Optimization of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: A New Therapeutic Challenge
by: Alessandra Iurlo, et al.
Published: (2021-02-01)

A proof-of-concept study with the tyrosine kinase inhibitor nilotinib in spondyloarthritis
by: Jacqueline E. Paramarta, et al.
Published: (2016-10-01)

First-line treatment strategies for newly diagnosed chronic myeloid leukemia: a network meta-analysis
by: Chen KK, et al.
Published: (2018-09-01)

A combination of sorafenib and nilotinib reduces the growth of castrate-resistant prostate cancer
by: Archibald M, et al.
Published: (2016-01-01)

Cardiotoxicity of tyrosine kinase inhibitors in chronic myelogenous leukemia therapy
by: Zhenshu Xu, et al.
Published: (2009-03-01)

Economic evaluation of dasatinib in the treatment of chronic myeloid leukemia patients resistant to imatinib in Chile
by: Milva Caputo, et al.
Published: (2011-04-01)

PHILADELPHIA CHROMOSOME
by: Habibullah Khan
Published: (2017-08-01)

Mutational analysis of T315I in patients with chronic myeloid leukemia who did not respond to second-generation tyrosine kinase inhibitors
by: Riyam Qusay Ibrahim Al-Jadir, et al.
Published: (2020-01-01)

Acute appendicitis revealing a diagnosis of chronic myelogenous leukemia
by: Rita Ahmad, et al.
Published: (2021-04-01)

Management of Chronic Myeloid Leukemia Patients During Pregnancy (Analysis of Literature and Practical Recommendations)
by: EYu Chelysheva, et al.
Published: (2019-03-01)

Toward an Improved Chronic Myelogenous Leukemia Treatment: Blocking the Stem Cell Factor–Mediated Innate Resistance With Anti–c-Kit Synthetic-Antibody Inhibitors
Published: (2015)

Dasatinib in the Management of Pediatric Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
by: Claudio Cerchione, et al.
Published: (2021-03-01)

Chronic Myeloid Leukemia Patient Registry in the Russian Federation: From Observational Studies to the Efficacy Evaluation in Clinical Practice
by: AG Turkina, et al.
Published: (2017-07-01)

Chronic Myeloid Leukemia: Long-Term Experience of Target Therapy
by: KM Abdulkadyrov, et al.
Published: (2016-01-01)

Acute Myelogenous Leukemia Mimicking Fulminant Periorbital Cellulitis
by: Abbas Bagheri, et al.
Published: (2013-01-01)